AVEO Pharmaceuticials is a cancer therapeutics company focused on discovering, developing and commercializing targeted cancer therapies. Co.'s primary drug candidate, tivozanib, is designed to provide an optimal blockade of the vascular endothelial growth factor ("VEGF") pathway by inhibiting three VEGF receptors: VEGF receptors 1, 2 and 3. In addition to tivozanib, Co. has a pipeline of monoclonal antibodies derived from its Human Response Platform™, a method of building preclinical models of human cancer. Ficlatuzumab, Co.'s secondary product candidate, is an antibody which binds to hepatocyte growth factor thereby blocking its function.
Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Service. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20
minutes; ETF data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.
